We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Next-Gen Sequencing May Improve Diagnose of Rare Diseases in Newborns

By LabMedica International staff writers
Posted on 13 Jun 2016
A pilot study suggests that a next-generation sequencing (NGS) test panel for newborns in neonatal intensive care units (NICUs) may improve the diagnosis of rare diseases, deliver results more quickly, and enable test performance in-hospital rather than outsourcing.

"Newborns admitted to the NICU with rare and complex diseases may benefit substantially from a timely molecular diagnosis through NGS," wrote Dr. More...
David Dyment, Children's Hospital of Eastern Ontario (CHEO; Ottawa, Ontario, Canada), and coauthors. Children with suspected rare genetic diseases usually undergo a battery of tests to determine a molecular diagnosis. Current practice involves testing of specific genes or a panel of genes, and these tests are often done outside the country because of limited availability within Canada. This means it may be months or even years before a diagnosis is made.

There are few studies to date looking at the feasibility and diagnostic success rate of NGS in the NICU. In the new report, the researchers conducted a pilot study with 20 newborns to determine the effectiveness of a targeted NGS panel that included all 4813 genes currently known to be associated with rare diseases. The 20 newborns presented with a wide range of complex medical issues, and half had neurologic symptoms such as seizures or hypotonia. NGS provided a molecular diagnosis for eight of the 20 infants (40%); in 2 infants the diagnoses had a direct impact on their medical management.

"This technique can be performed in a hospital-based laboratory without the need to send samples away," stated Dr. Dyment, "This will allow for diagnoses to be made quickly, providing answers to anxious families and potentially life-saving interventions in some cases."

The researchers suggested that adopting NGS in hospitals will greatly increase the ability to diagnose rare diseases and treat children while reducing healthcare financial costs. "It can also indicate whether other family members may be at risk of the same disease and provide an accurate recurrence risk for future pregnancies," wrote Dr. Sarah Bowdin, Clinical & Metabolic Genetics, Hospital for Sick Children (SickKids; Toronto, Ontario, Canada) in a related commentary, " Building strong partnerships with specialists such as neonatologists, intensive care physicians, and genetics laboratories is critical to ensure the success of this diagnostic tool.

The study, by Daoud H et al, and the commentary, by Bowdin SC, were published May 30, 2016, in the Canadian Medical Association Journal.

Related Links:
Children's Hospital of Eastern Ontario


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.